Acarbose

An inhibitor of alpha glucosidase that retards the digestion and absorption of carbohydrates in the small intestine and hence reduces the increase in blood-glucose concentrations after a carbohydrate load. It is given orally to non-insulin dependent diabetes mellitus patients where diet modification or oral hypoglycemic agents do not control their condition. (From Martindale The Extra Pharmacopoeia, 31st ed)

Also Known As:

Networked: 549 relevant articles (101 outcomes, 153 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Chiasson, Jean-Louis: 13 articles (07/2014 - 06/2002)
2.	Hanefeld, Markolf: 8 articles (07/2012 - 06/2002)
3.	Maffioli, Pamela: 7 articles (11/2015 - 03/2009)
4.	Derosa, Giuseppe: 7 articles (11/2015 - 03/2009)
5.	Hanefeld, M: 7 articles (05/2014 - 03/2002)
6.	Laakso, Markku: 6 articles (04/2007 - 06/2002)
7.	D'Angelo, Angela: 5 articles (11/2015 - 03/2009)
8.	Kalinowski, Jörn: 5 articles (01/2015 - 01/2012)
9.	Pühler, Alfred: 5 articles (01/2015 - 01/2012)
10.	Schnell, Oliver: 4 articles (02/2015 - 01/2010)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2005 - "The STOP-NIDDM trial confirmed the efficacy of acarbose in decreasing the risk of diabetes by 36% in similar high risk population. " 01/01/2006 - "The STOP-NIDDM Trial demonstrated that, in subjects with IGT, acarbose treatment was effective in reducing the risk of type 2 diabetes. " 02/16/1997 - "Acarbose was shown to be effective in treating NIDDM and to be safe and well-tolerated." 03/01/1989 - "These findings demonstrate that acarbose is effective in moderating the metabolic effects of NIDDM in this diabetic rodent model, and suggest that acarbose may have potential in the management of NIDDM in humans." 02/01/1996 - "These results indicate that treatment with acarbose is safe and effective in adjunct to dietary therapy for the treatment of NIDDM."
2.	Hyperglycemia 06/01/2012 - "Acarbose treatment was effective in patients with uncontrolled type 2 diabetes and in patients with apparently good metabolic control owing to its positive effect on postprandial hyperglycemia (P < 0.0001). " 11/01/1996 - "Acarbose is effective in reducing postprandial hyperglycemia. " 08/01/2011 - "In addition, acarbose treatment was helpful in preventing the deposition of such fibres, as well the increase in oxidative stress induced by hyperglycemia." 04/07/2011 - "  The present study showed that the beneficial effects of acarbose on arterial stiffness are mediated by an improvement of postprandial hyperglycemia and vascular remodeling markers. " 03/01/2013 - "Furthermore, all the extracts (50 mg/kg BW) showed a significant (p<0.05) effect on postprandial hyperglycemia in diabetic mice as compared with a model group, and the suppression of EP was not significantly (p>0.05) different from that of acarbose at the same dosage (50 mg/kg BW), which indicate that these fractions could be developed as potential anti-diabetic agents."
3.	Diabetes Mellitus 01/01/1999 - "Acarbose observational study performed in the routine treatment conditions confirmed efficacy of the drug in diabetes mellitus, for both--carbohydrate and lipid metabolism. " 09/01/1998 - "Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials." 09/01/1996 - "A review of the safety and efficacy of acarbose in diabetes mellitus." 01/01/2005 - "The efficacy and tolerability of acarbose were examined in a postmarketing surveillance study of 27 803 patients with diabetes mellitus (26 044 were diagnosed as having type 2 diabetes) over a 12-week treatment period. " 01/01/2005 - "Evaluation of the efficacy and tolerability of acarbose in patients with diabetes mellitus : a postmarketing surveillance study."
4.	Body Weight (Weight, Body) 01/01/2005 - "In this analysis, glycemic control, triglyceride levels, body weight and systolic blood pressure was also significantly improved during acarbose treatment. " 01/01/2004 - "Glycaemic control, triglyceride levels, body weight and systolic blood pressure also improved significantly during acarbose treatment. " 09/01/2003 - "Loss of body weight was also significantly greater for acarbose than placebo subjects. " 03/01/1997 - "The PROTECT study confirms the previously demonstrated efficacy and safety of acarbose in improving glycemic control in patients with type II diabetes regardless of a patient's age, body weight, ethnic background, time since diagnosis, or severity of disease. " 11/01/2014 - "Eligible studies were randomised controlled trials of acarbose monotherapy in populations with hyperglycaemia of more than 12-week duration that provided data on body weight (BW) or body mass index (BMI). "
5.	Insulin Resistance 02/01/2009 - "Further, recently, acarbose has been shown to improve insulin resistance in vivo. " 07/01/2011 - "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study." 07/01/2011 - "We evaluated the effects of acarbose on insulin resistance parameters in diabetic patients before and after a standardized oral fat load (OFL). " 01/25/2011 - "Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load." 04/01/2006 - "In addition, acarbose treatment prevented the deterioration in insulin resistance with increasing age. "

Related Drugs and Biologics

1.	Metformin (Glucophage)
2.	Glucose (Dextrose)
3.	alpha-Glucosidases (Acid Maltase)
4.	Insulin (Novolin)
5.	Acarbose
6.	Blood Glucose (Blood Sugar)
7.	nateglinide (Starlix)
8.	Glucosidases
9.	Hypoglycemic Agents (Hypoglycemics)
10.	Thiazolidinediones

Related Therapies and Procedures

1.	Long-Term Care
2.	Drug Therapy (Chemotherapy)
3.	Fundoplication
4.	Exercise Therapy (Therapy, Exercise)
5.	Oral Administration